No tools account for prostate cancer-specific features or can simultaneously identify BRCA2 deficient (BRCA2d), CDK12 deficient (CDK12d), and MMRd mCRPC from individual patient samples. This evidence concerns the gene BRCA2 and prostate carcinoma.